Navigation Links
Watson Prices $850 Million of Senior Unsecured Notes
Date:8/18/2009

MORRISTOWN, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a specialty pharmaceutical company, today announced the pricing of a debt offering of $450.0 million of 5.000% senior notes due 2014 and $400.0 million of 6.125% senior notes due 2019, for a total offering of $850.0 million in aggregate principal amount. The offering is expected to close on August 24, 2009, subject to market conditions and other factors.

Watson intends to use the net proceeds from the offering to fund a portion of the cash consideration for Watson's previously announced acquisition of the privately-held Arrow Group, to redeem the $575.0 million aggregate principal amount outstanding of its contingent senior debentures due 2023 and to repay $100.0 million of term loan borrowings under its existing credit agreement. The senior unsecured notes offering is not conditioned on the completion of the acquisition of the Arrow Group and the notes are not subject to a mandatory redemption if the acquisition is not consummated.

Watson has filed a registration statement (including a prospectus supplement and accompanying prospectus) with the SEC relating to the offering. This offering of senior unsecured notes may be made only by means of a prospectus supplement and an accompanying prospectus. Before investing, investors should read the prospectus, the prospectus supplement and other documents that the company has filed with the SEC for more complete information about Watson Pharmaceuticals, Inc. and this offering. Investors may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Watson Announces Limited Recall Of Fentanyl Transdermal System
2. Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
3. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
4. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
5. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
6. Watson CFO Mark W. Durand to Take Leave of Absence
7. Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
8. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
9. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
10. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
11. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
(Date:12/25/2014)... Santa Rosa, CA (PRWEB) December 25, 2014 ... emergency department visits and 2 million hospital admissions across ... Control and Prevention ). The CDC’s National Hospital ... emergency departments through a survey conducted in 2010. They ... emergency department visits that resulted in a primary diagnosis ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... playing a major role in responding to the ... who experience psychiatric and substance use,conditions each year, ... Association of Psychiatric Health Systems (NAPHS) released today., ... distinct views of behavioral,healthcare delivery. One chapter provides ...
... N.J., May 16 Barbara Senich, B.S.N., M.B.A.,M.P.H., ... honored by,Executive Women of New Jersey (EWNJ) at ... The biennial event, held May 15, 2008 at ... distinction in New,Jersey who are senior executives or ...
... in mammalian embryos prevents the development of a healthy ... College of Wisconsin, Milwaukee, has found. , The study, ... Biology, was led by Stephen Duncan, Ph.D., professor of ... , This is the first study that has successfully ...
... ROCHESTER, Minn. -- Adding a second monoclonal antibody drug ... B-cell lymphoma, according to Mayo Clinic researchers working with ... ). Results of this interim analysis were released May ... the American Society of Clinical Oncology. , Researchers ...
... Shandong, China, May 16 /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. ... a leading manufacturer and distributor,of high-quality, pharmaceutical grade ... the three months ended March 31, 2008., ... -- Sales increased 64.8% to $20.7 million ...
... Inc. (Nasdaq: JAZZ ) announced today that Robert ... at two,upcoming investor conferences., Mr. Myers will speak ... London at 9:30 a.m. BST (4:30 a.m. EDT) on,Wednesday, ... Mr. Myers will present at the FBR Capital,Markets Spring ...
Cached Medicine News:Health News:New NAPHS Annual Survey Tracks Behavioral Treatment Trends 2Health News:Roche Vice President Senich Honored at EWNJ 'Salute to Policy Makers' 2Health News:Roche Vice President Senich Honored at EWNJ 'Salute to Policy Makers' 3Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2Health News:Adding epratuzumab to standard therapy 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)...  The American Diabetes Association is recommending a ... with diabetes and that all people with diabetes ... in keeping with recent changes to guidelines for ... of Cardiology (ACC) and American Heart Association (AHA). ... changes to the Association,s annual revised Standards of ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... Life Sciences, Inc. (Nasdaq: CALP ), a ... and life sciences research, today announced that the company ... for the Environmental Protection Agency,s (EPA) Phase II ToxCast™ ... Protection Agency (EPA) announced the next phase of toxicity ...
... 2010 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ... diseases associated with inflammation, today announced that their product ... Pediatric Research Award at the Third Congress of the ... where Dr. Daniele De Luca, MD, PhDst at the ...
Cached Medicine Technology:Caliper Continues Participation in EPA's Expanded ToxCast Program; Receives Remaining Phase II Compounds for Screening in Fourth Quarter 2Caliper Continues Participation in EPA's Expanded ToxCast Program; Receives Remaining Phase II Compounds for Screening in Fourth Quarter 3Varespladib Receives 2010 European Society Pediatric Research Award 2Varespladib Receives 2010 European Society Pediatric Research Award 3
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... small portable unit weighing less than thirty ... dependability and uncompromising image quality. Compatible with ... is a cost effective solution for a ... keyboard is durable and easy to operate. ...
The EUB-525 is a mid-size system with a full feature set. Capable of B-mode, M-mode, Doppler, Color Flow and Color Angiography it performs a variety of tasks in a simple and straightforward fashion....
Medicine Products: